Exact Sciences (NASDAQ:EXAS) Stock, Options inhabituelles

Exact Sciences

Exact Sciences Corporation - Common Stock

Aperçu

Actualités

Gains

Options

Orientation

Évaluations des analystes

Transactions internes

Intérêt court

Commerces gouvernementaux

Rapport sur les stocks

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Comments

Exact Sciences Options Inhabitueles

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Benzinga

Benzinga

Benzinga

Comments

Exact Sciences Options Inhabitueles

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL